LF 1695

Description

LF 1695 is a synthetic immunomodulator.

in vitro

This was further confirmed by the fact that LF 1695 inhibited the second wave of platelet aggregation induced by ADP as well as arachidonic acid effects. Incubation of platelets with [14C]arachidonic acid in the presence of 60 microM LF 1695 resulted in a strong inhibition of arachidonic acid incorporation into the various cell lipids, indicating that arachidonic acid mobilization might be due to inhibition of reacylation processes._x000D_ _x000D_ Reference: Biochem Pharmacol. 1989 Sep 1;38(17):2763-72. https://pubmed.ncbi.nlm.nih.gov/2505775/

in vivo

CBA, H2k mice receiving a lethal dose of irradiation were injected with spleen cells from LF 1695-treated or untreated C57 Bl/6, H2b mice via different routes. Mice treated intraperitoneally with LF 1695 at 2.5 or 5 mg/kg/day showed an increase of GvHR intensity with splenic index of 1.71 and 1.80, respectively. When the animals were treated continuously through drinking water containing LF 1695 (4 mg/kg, 10 mg/kg or 100 mg/kg), these ratios were: 1.82, 1.10 and 1.37, respectively. Finally, LF 1695 enhanced GvHR significantly when used at low doses, while high doses induced a decrease of GvHR intensity._x000D_ _x000D_ Reference: Int J Immunopharmacol. 1991;13(5):599-604. https://pubmed.ncbi.nlm.nih.gov/1838358/